Additionally, activation of platelet TLR4 by SARS-CoV-2 may lead to activation of pro-thrombotic cascades, and therefore TLR4 antagonists can attenuate COVID-19 complications [136], with prolonged TLR4 activations leading to a marked activation of STAT3 and NF-κB signaling pathway and induction of pro-inflammatory activations [137]. This evidence concerns the gene NFKB1 and COVID-19.